Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Solid Tumor: early-phase trial registry
133 of 190 indexed Advanced Solid Tumor trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #56 of 28,707 conditions by registered trial count.
190 US clinical trials · 133 currently recruiting · #56 of 28,707 conditions by registered trial count
Advanced Solid Tumor: 190 US clinical trials tracked, 133 recruiting.
Advanced Solid Tumor is the subject of 190 registered US clinical trials on ClinicalTrials.gov, 133 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 186 in Phase 1-2 (earlier-stage). The most active sponsor is Daiichi Sankyo, running 7 of these trials.
Enrollment posture brief
Registry condition advanced-solid-tumor
OPEN 133 | RECR 70% | LATE 0 | EARLY 186 | RANK #56 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Anatomic Stage IV Breast Cancer AJCC v8 (70% recruiting · 60 trials)
Advanced Solid Tumor lists 133 open slots (70% of 190 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Solid Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Solid Tumor is recruiting above its size-band peers.
133 of 190 indexed trials (70%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Advanced Solid Tumor trials is spread across many organizations.
Daiichi Sankyo accounts for 7 of 190 trials (3.7%). 135 distinct sponsors appear on at least one study for this condition label.
-
Typical Advanced Solid Tumor enrolment sits around 141 participants.
Median target enrolment is 141 among the 190 trials that report a genuine target (sentinel values excluded). 73 of those (38.4%) plan for fewer than 100 participants.
-
Advanced Solid Tumor research is mostly interventional.
188 interventional and 2 observational studies make up this index (98.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
190 total, page 2 of 4
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Volastra Therapeutics
NCT05902988
SNV1521 in Participants with Advanced Solid Tumors
Synnovation Therapeutics
NCT06220864
A Study of DS5361b in Participants With Advanced Solid Tumors
Daiichi Sankyo
NCT07182591
SW-682 in Advanced Solid Tumors
SpringWorks Therapeutics
NCT06251310
Study of GS-5319 in Adults With Solid Tumors
Gilead Sciences
NCT07128303
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
Jazz Pharmaceuticals
NCT06108050
Study of LP-184 in Patients With Advanced Solid Tumors
Lantern Pharma
NCT05933265
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
OncoResponse
NCT06090266
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
BeOne Medicines
NCT06625593
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
CJ Bioscience
NCT05877430
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience
NCT05267626
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
Eikon Therapeutics
NCT06253130
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Plexium
NCT07284186
A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Coherus Oncology
NCT06657144
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
1ST Biotherapeutics
NCT05761223
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
PharmaMar
NCT05076396
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics
NCT06586957
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
Oncomatryx Biopharma S.L.
NCT05547321
A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
Latticon Antibody Therapeutics
NCT06277219
A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
OBI Pharma
NCT07124117
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Eisbach Bio
NCT06525298
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
Day One Biopharmaceuticals
NCT04775485
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma
NCT05873686
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
Xilio Development
NCT04896697
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
NCT06974110
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma
NCT06362369
Clinical Trial of PM54 in Advanced Solid Tumors Patients.
PharmaMar
NCT05841563
A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
Ningbo Newbay Technology Development Co.
NCT05036291
A Beta-only IL-2 ImmunoTherapY Study
Medicenna Therapeutics
NCT05086692
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
Edgewood Oncology
NCT04872166
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Alterome Therapeutics
NCT06533059
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
Lantern Pharma
NCT06132503
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Strand Therapeutics
NCT06249048
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
BeOne Medicines
NCT07226349
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
Ipsen
NCT07213830
A Study of KK2269 in Adult Participants With Solid Tumors
Kyowa Kirin Co.
NCT06266299
This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors
ABL Bio
NCT04762641
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
InSilico Medicine Hong Kong Limited
NCT06566079
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Ankyra Therapeutics
NCT06171750
64Cu-GRIP B in Patients With Advanced Malignancies
Rahul Aggarwal
NCT05888532
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Clasp Therapeutics
NCT06778863
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Nectin Therapeutics
NCT05378425
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
BeiGene
NCT06803680
Study of APR-1051 in Patients With Advanced Solid Tumors
Aprea Therapeutics
NCT06260514
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
TORL Biotherapeutics
NCT05103683
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
BeiGene
NCT06598800
Study of CHS-114 in Participants With Advanced Solid Tumors
Coherus Oncology
NCT05635643
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Cullinan Therapeutics
NCT06035744
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
BeOne Medicines
NCT07222267
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
NCT06833008
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 180 |
| Phase 2 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Solid Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Solid Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Solid Tumor page
190 registered trials, 133 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 133 Advanced Solid Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Daiichi Sankyo sponsors the most Advanced Solid Tumor trials on record, review their full trial history before evaluating a specific study. See Daiichi Sankyo's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Solid Tumor condition card totals 190 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.